Home / Reports

Reports

EU health spending in 2010 decreases for first time since 1975

Health spending fell across the EU in 2010, governments affected by continuing austerity measures tried to save money by reducing spending on health, according to Health at a Glance: Europe 2012, a new joint report by the OECD and the European Commission.

Generic drug prices decrease, brand-name prices increase

Over the last year brand-name drugmakers have raised prices by 13.3%, more than six times the consumer inflation rate. Generic drug prices, on the contrary; actually decreased by 21.9% during the same period.

Biosimilar policies in the UK

The UK was placed in 10th position in the global pharmaceutical markets in 2011 [1]. The UK also had some of the lowest prices for medicines in Europe [2]. Cost pressures and a well-developed generics market mean that the UK is likely to be a fast-adopter of biosimilars. However, relatively low usage of biologicals reduces the UK’s attractiveness as a biosimilars market [3].

Biosimilar policies in Spain

Spain is Europe’s fifth largest pharmaceutical market [1], however, in 2009, biosimilars accounted for less than 5% of the total biologicals market [2].

Future biosimilar targets

It seems biological medicines are set to play a major part in the pharmaceutical industry’s future and they already play a major part in its current growth [1]. At the moment, biologicals account for 10–15% of the pharmaceutical market. More than one-fifth of new medicines launched on the world market each year are now biotechnology-derived.

Generic medicine switches confuse patients and reduce adherence

Switching between generic medicines without explaining the reason to the patient can undermine trust in pharmacists, the Aston Medication Adherence Study (AMAS) has found [1].

EMA report shows generics applications down but biosimilars up

EMA’s mid-year report for 2012 has shown that the number of generics applications is much lower than the agency has predicted, while for biosimilars it is the opposite.

Stakeholders are key allies for biosimilar producers

Many different drug developers could potentially contribute to the biosimilars market, which is projected to expand rapidly, achieving sales of between US$1.9–2.6 billion by 2015. It is vital, however, to take into account the requirements of different stakeholders in order to develop appropriate strategies for success, as highlighted in a recent IMS Health report [1].

Australian patients ‘very positive’ about generics

A new survey shows 75% of Australians believe that the government should offer a price discount to consumers who choose generics.

ABPI concerned about medicines misconceptions

The Association of the British Pharmaceutical Industry (ABPI) represents innovative research-based biopharmaceutical companies in the UK. In a new survey commissioned by the association issues of misunderstandings by the British public have been highlighted regarding the cost and value of medicines in the UK.